Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver

Annals of Surgical Oncology

Volumn 10, Issue 8, 2003, Pages 852-862

  Cusack Jr , James C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Apoptosis; Chemotherapy resistance; Colon cancer; Liver metastases; NF B

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LEVAMISOLE; MITOMYCIN C; PROTEASOME; TRANSCRIPTION FACTOR;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL PROTECTION; CHEMOSENSITIVITY; COLORECTAL CANCER; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME INHIBITION; GENE MUTATION; HUMAN; LIVER METASTASIS; REVIEW; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; LIVER TUMOR; METABOLISM; METASTASIS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; NF-KAPPA B;

EID: 1542649570     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.07.518     Document Type: Review

References (55)

1. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121-39.
2. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
3. Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-9.
4. Cunningham D. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur J Cancer 1996;32A:S1.
5. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187:127-37.
6. Wu GS, El-Deiry WS. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 1996;2:623-33.
7. Kastan MB. Molecular determinants of sensitivity to antitumor agents. Biochim Biophys Acta 1999;1424:R37-42.
8. El-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997;9:79-87.
9. Baldini N. Multi-drug resistance - a multiplex phenomenon. Nat Med 1997;3:378-80.
10. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1996;78:539-42.
11. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996;2:574-7.
12. Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998;58:4453-60.
13. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998;16:3158-68.
14. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997; 40:S13-9.
15. Shi MM, Bleavins MR, de la Iglesia FA. Technologies for detecting genetic polymorphisms in pharamacogenics. Mol Diagn 1999; 4:343-51.
16. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995;40: 523.
17. De Angelis P, Stokke T, Smedshammer L, et al. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 1995;72:307-11.
18. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry, and microsequencing. Electrophoresis 1999;20:2961-9.
19. Mini E, Biondi C, Morganti M, et al. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol Res 1999;11:437-45.
20. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
21. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319: 525-32.
22. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
23. Grasl-Kraupp B, Ruttkay-Nedecky B, Mullauer L, et al. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology 1997;25:906-12.
24. Dixon SC, Soriano BJ, Lush RM, Borner MM, Figg WD. Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. Ann Pharmacother 1997;31:76.
25. Bellamy CO, Clarke AR, Wyllie AH, Harrison DJ. p53 deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage. Faseb J 1997;11:591-9.
26. Soini Y, Virkajarvi N, Lehto VP, Paakko P. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br J Cancer 1996;73:1025-30.
27. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
28. Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature 1997;389:300-5.
29. Symonds H, Krall L, Remington L, et al. p-53 dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78: 703-11.
30. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Institute 1997;89: 21-39.
31. Friedman SL, Shaulian E, Littlewood T, et al. Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells. Oncogene 1997;15:63-70.
32. Wang C-Y, Mayo M, Baldwin ASJ. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science 1996;274:784-7.
33. Beg AA, Baltimore D. An essential role for NF-kB in preventing TNF-alpha-induced cell death. Science 1996;274:782.
34. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kB activation prevents cell death. Cell 1996;87:565.
35. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma JM. Suppression of TNF-alpha-induced apoptosis by NF-kB. Science 1996;274:787.
36. Wang C-Y, Mayo M, Korneluk RG, Goeddel DV, Baldwin ASJ. NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998;281: 1680-3.
37. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996;4:387-96.
38. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kB activation. Cell 1995;81:495-504.
39. Santana P, Pena LA, Haimovitz-Friedman A, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996;86:189-99.
40. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992;13:151-3.
41. Wang C-Y, Cusack JC, Liu R, Baldwin ASJ. Control of inducible chemoresistance: enhanced antitumor efficacy via increased apoptosis by inhibition of NF-kB. Nat Med 1999;5:412-7.
42. Cusack JC, Wang C-Y, Liu R, Baldwin ASJ. Chemosensitization of human fibrosarcoma xenografts following adenoviral-mediated transfer of the NF-kB super-repressor IkBa gene. Cancer Gene Therapy 1997;4:S44.
43. Cusack JC, Wang C-Y, Liu R, Baldwin ASJ. Chemosensitization of colorectal cancer cells by expression of the NF-kB super-repressor IkBa. Surg Forum 1997;48:815-7.
44. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27.
45. Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 1999;6:303-13.
46. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795-804.
47. Adams J, Palombella VJ, Elliott PJ, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
48. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998;58:4342-8.
49. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 2OS and 26S proteasomes. Annu Rev Biochem 1996;65:801-47.
50. Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 1995;2:503-8.
51. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274:1652-9.
52. Grisham MB, Palombella VJ, Elliott PJ, et al. Inhibition of NF-kB activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol 1999;300:345-63.
53. Cusack JC, Liu R, Baldwin ASJ. Inducible chemoresistance to 7-ethyl-10-(4-(1-piperidino)-1-piperidino)-carbonyloxycamptothe ein (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kB activation. Cancer Res 2000;60:2323-30.
54. Cusack JC, Liu R, Houston MA, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic NF-kB Inhibition. Cancer Res 2001;61:3535-40.
55. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997;272:24159-64.